Skip to main content

Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review.

Publication ,  Journal Article
Keefe, RSE; McClintock, SM; Roth, RM; Doraiswamy, PM; Tiger, S; Madhoo, M
Published in: J Clin Psychiatry
August 2014

OBJECTIVE: Cognitive impairment frequently accompanies major depressive disorder (MDD) and can persist during remission. This review examined pharmacotherapy effects on cognitive function in MDD. DATA SOURCES: PubMed and EMBASE searches were conducted on July 30, 2013, for English language reports of cognitive assessments following pharmacologic monotherapy or augmentation therapy in MDD. STUDY SELECTION: A total of 43 research reports were identified (31 monotherapy [8 placebo-controlled, 11 active-comparator, 12 open-label], 12 augmentation therapy [7 placebo-controlled, 5 open-label]). DATA EXTRACTION: Results reported in each publication were examined for open-label and placebo- or active comparator-controlled studies. RESULTS: Studies varied widely in terms of size (median, 50 participants; interquartile range, 21-143 participants), populations examined, duration (median, 8 weeks; interquartile range, 6-12 weeks), and neurocognitive assessments used. Most individual studies reported some benefit to cognition with pharmacotherapy, but there was no pattern of response in specific domains and only 12% of individually analyzed changes favored active treatment over placebo or untreated healthy controls. Sample weighted mean effect sizes revealed that verbal memory improved with monotherapy, while the largest treatment effect with augmentation therapy was for visual memory. CONCLUSIONS: Pharmacotherapy may have benefit in reducing cognitive impairment in MDD, with augmentation therapy being a potential approach for addressing cognitive deficits that persist after monotherapy has brought about clinical response or remission. However, given the wide variability in study design and treatment duration across studies, these findings should be interpreted cautiously. More definitive research is required before firm conclusions can be reached.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Psychiatry

DOI

EISSN

1555-2101

Publication Date

August 2014

Volume

75

Issue

8

Start / End Page

864 / 876

Location

United States

Related Subject Headings

  • Psychotropic Drugs
  • Psychiatry
  • Neuropsychological Tests
  • Humans
  • Drug Therapy, Combination
  • Depressive Disorder, Major
  • Cognition Disorders
  • Antidepressive Agents
  • 3202 Clinical sciences
  • 17 Psychology and Cognitive Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Keefe, R. S. E., McClintock, S. M., Roth, R. M., Doraiswamy, P. M., Tiger, S., & Madhoo, M. (2014). Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. J Clin Psychiatry, 75(8), 864–876. https://doi.org/10.4088/JCP.13r08609
Keefe, Richard S. E., Shawn M. McClintock, Robert M. Roth, P Murali Doraiswamy, Steven Tiger, and Manisha Madhoo. “Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review.J Clin Psychiatry 75, no. 8 (August 2014): 864–76. https://doi.org/10.4088/JCP.13r08609.
Keefe RSE, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. J Clin Psychiatry. 2014 Aug;75(8):864–76.
Keefe, Richard S. E., et al. “Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review.J Clin Psychiatry, vol. 75, no. 8, Aug. 2014, pp. 864–76. Pubmed, doi:10.4088/JCP.13r08609.
Keefe RSE, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. J Clin Psychiatry. 2014 Aug;75(8):864–876.

Published In

J Clin Psychiatry

DOI

EISSN

1555-2101

Publication Date

August 2014

Volume

75

Issue

8

Start / End Page

864 / 876

Location

United States

Related Subject Headings

  • Psychotropic Drugs
  • Psychiatry
  • Neuropsychological Tests
  • Humans
  • Drug Therapy, Combination
  • Depressive Disorder, Major
  • Cognition Disorders
  • Antidepressive Agents
  • 3202 Clinical sciences
  • 17 Psychology and Cognitive Sciences